Literature DB >> 25987627

Effect of Variants of Penicillin-Binding Protein 2 on Cephalosporin and Carbapenem Susceptibilities in Neisseria gonorrhoeae.

Amrita Bharat1, Walter Demczuk1, Irene Martin1, Michael R Mulvey2.   

Abstract

To characterize the relationship between penicillin-binding protein 2 (PBP2/penA) and susceptibility to extended-spectrum cephalosporins (ESCs) and carbapenem antibiotics, we compared 17 PBP2 variants in Neisseria gonorrhoeae. Nonmosaic and mosaic variants of PBP2 caused decreased susceptibility to ESCs and, to a lesser extent, to carbapenems. An A501P substitution in mosaic XXXIV_A501P conferred decreased susceptibility to ESCs but restored carbapenem susceptibility to wild-type levels. These results could aid the molecular surveillance of antimicrobial resistance to these agents.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25987627      PMCID： PMC4505281          DOI： 10.1128/AAC.05143-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  21 in total

1.  Treatment failure of pharyngeal gonorrhoea with internationally recommended first-line ceftriaxone verified in Slovenia, September 2011.

Authors:  M Unemo; D Golparian; M Potočnik; S Jeverica
Journal:  Euro Surveill       Date:  2012-06-21

2.  Update to CDC's Sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2012-08-10       Impact factor: 17.586

3.  Failure of 500 mg of ceftriaxone to eradicate pharyngeal gonorrhoea, Australia.

Authors:  Marcus Y Chen; Kerrie Stevens; Robin Tideman; Angelo Zaia; Takehiro Tomita; Christopher K Fairley; Monica Lahra; David Whiley; Geoff Hogg
Journal:  J Antimicrob Chemother       Date:  2013-02-06       Impact factor: 5.790

4.  Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone.

Authors:  Makoto Ohnishi; Daniel Golparian; Ken Shimuta; Takeshi Saika; Shinji Hoshina; Kazuhiro Iwasaku; Shu-ichi Nakayama; Jo Kitawaki; Magnus Unemo
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

5.  Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada.

Authors:  Vanessa G Allen; Leo Mitterni; Christine Seah; Anuradha Rebbapragada; Irene E Martin; Colin Lee; Heather Siebert; Lynn Towns; Roberto G Melano; Donald E Low
Journal:  JAMA       Date:  2013-01-09       Impact factor: 56.272

6.  High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure.

Authors:  Magnus Unemo; Daniel Golparian; Robert Nicholas; Makoto Ohnishi; Anne Gallay; Patrice Sednaoui
Journal:  Antimicrob Agents Chemother       Date:  2011-12-12       Impact factor: 5.191

7.  In vitro activity of ertapenem versus ceftriaxone against Neisseria gonorrhoeae isolates with highly diverse ceftriaxone MIC values and effects of ceftriaxone resistance determinants: ertapenem for treatment of gonorrhea?

Authors:  Magnus Unemo; Daniel Golparian; Athena Limnios; David Whiley; Makoto Ohnishi; Monica M Lahra; John W Tapsall
Journal:  Antimicrob Agents Chemother       Date:  2012-04-30       Impact factor: 5.191

8.  Ceftriaxone treatment failure of pharyngeal gonorrhoea verified by international recommendations, Sweden, July 2010.

Authors:  M Unemo; D Golparian; A Hestner
Journal:  Euro Surveill       Date:  2011-02-10

9.  Identification of amino acids conferring high-level resistance to expanded-spectrum cephalosporins in the penA gene from Neisseria gonorrhoeae strain H041.

Authors:  Joshua Tomberg; Magnus Unemo; Makoto Ohnishi; Christopher Davies; Robert A Nicholas
Journal:  Antimicrob Agents Chemother       Date:  2013-04-15       Impact factor: 5.191

10.  Antimicrobial susceptibility and genetic characteristics of Neisseria gonorrhoeae isolates from Vietnam, 2011.

Authors:  Birgitta Olsen; Thi Lan Pham; Daniel Golparian; Emma Johansson; Hau Khang Tran; Magnus Unemo
Journal:  BMC Infect Dis       Date:  2013-01-25       Impact factor: 3.090
View more
  6 in total

1.  WGS to predict antibiotic MICs for Neisseria gonorrhoeae.

Authors:  David W Eyre; Dilrini De Silva; Kevin Cole; Joanna Peters; Michelle J Cole; Yonatan H Grad; Walter Demczuk; Irene Martin; Michael R Mulvey; Derrick W Crook; A Sarah Walker; Tim E A Peto; John Paul
Journal:  J Antimicrob Chemother       Date:  2017-07-01       Impact factor: 5.790

2.  Characterization of VCC-1, a Novel Ambler Class A Carbapenemase from Vibrio cholerae Isolated from Imported Retail Shrimp Sold in Canada.

Authors:  Chand S Mangat; David Boyd; Nicol Janecko; Sarah-Lynn Martz; Andrea Desruisseau; Michael Carpenter; Richard J Reid-Smith; Michael R Mulvey
Journal:  Antimicrob Agents Chemother       Date:  2016-01-11       Impact factor: 5.191

3.  Antimicrobial susceptibility of Neisseria gonorrhoeae isolates from Hefei (2014-2015): genetic characteristics of antimicrobial resistance.

Authors:  Fa-Xing Jiang; Qian Lan; Wen-Jing Le; Xiao-Hong Su
Journal:  BMC Infect Dis       Date:  2017-05-25       Impact factor: 3.090

4.  Mismatch Amplification Mutation Assay-Based Real-Time PCR for Rapid Detection of Neisseria gonorrhoeae and Antimicrobial Resistance Determinants in Clinical Specimens.

Authors:  Valentina Donà; Joost H Smid; Sara Kasraian; Dianne Egli-Gany; Ferah Dost; Fatime Imeri; Magnus Unemo; Nicola Low; Andrea Endimiani
Journal:  J Clin Microbiol       Date:  2018-08-27       Impact factor: 5.948

5.  Antimicrobial Resistance Profiles of Human Commensal Neisseria Species.

Authors:  Maira Goytia; Symone T Thompson; Skylar V L Jordan; Kacey A King
Journal:  Antibiotics (Basel)       Date:  2021-05-06

Review 6.  Resistance to β-Lactams in Neisseria ssp Due to Chromosomally Encoded Penicillin-Binding Proteins.

Authors:  André Zapun; Cécile Morlot; Muhamed-Kheir Taha
Journal:  Antibiotics (Basel)       Date:  2016-09-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.